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Vaccination with peptide 10 (P10), derived from the Paracoccidioides brasiliensis glycoprotein 43 (gp43), induces a Th1 response
that protects mice in an intratracheal P. brasiliensis infection model. Combining P10 with complete Freund’s adjuvant (CFA) or
other adjuvants further increases the peptide’s antifungal effect. Since dendritic cells (DCs) are up to 1,000-fold more efficient at
activating T cells than CFA, we examined the impact of P10-primed bone-marrow-derived DC vaccination in mice. Splenocytes
from mice immunized with P10 were stimulated in vitro with P10 or P10-primed DCs. T cell proliferation was significantly in-
creased in the presence of P10-primed DCs compared to the peptide. The protective efficacy of P10-primed DCs was studied in
an intratracheal P. brasiliensis model in BALB/c mice. Administration of P10-primed DCs prior to (via subcutaneous vaccina-
tion) or weeks after (via either subcutaneous or intravenous injection) P. brasiliensis infection decreased pulmonary damage and
significantly reduced fungal burdens. The protective response mediated by the injection of primed DCs was characterized mainly
by an increased production of gamma interferon (IFN-) and interleukin 12 (IL-12) and a reduction in IL-10 and IL-4 compared
to those of infected mice that received saline or unprimed DCs. Hence, our data demonstrate the potential of P10-primed DCs as
a vaccine capable of both the rapid protection against the development of serious paracoccidioidomycosis or the treatment of
established P. brasiliensis disease.
Paracoccidioidomycosis (PCM) is a systemic granulomatousdisease initiated by the inhalation of Paracoccidioides brasil-
iensis conidia, a thermally dimorphic fungus. It is widespread in
Latin America, affecting mainly rural workers. Systemic mycoses
are the 10th leading cause of death due to infectious diseases in
Brazil (26, 27). Notably, approximately 1,853 (51.2%) of 3,583
confirmed deaths in Brazil due to systemic mycoses from 1996 to
2006 were caused by PCM (31). However, since PCM is not yet
included in the national mandatory disease notification system,
the true annual incidence of clinically significant PCM in Brazil is
not known.
First described by Puccia et al. in 1986 (33), the immunologi-
cally dominant glycoprotein of 43 kDa, gp43, is currently the ma-
jor diagnostic antigen of P. brasiliensis (12). The gp43 gene has
been cloned and sequenced (11). It encodes a polypeptide of 416
amino acids (Mr of 45,947) with a leader peptide of 35 residues,
and the mature protein has a single high mannoseN-glycosylated
site (11). A B cell-reacting epitope in gp43 has been suggested (8,
43), and the H-2d restricted T-cell epitope has been mapped to a
15-mer peptide called peptide 10 (P10) (39). Different 12-mer
sequences containing the hexapeptide HTLAIR induce prolifera-
tion of lymph node cells from mice sensitized to gp43 or infected
with P. brasiliensis, and the lymphoproliferation induced by either
P10 or gp43 involves type 1 CD4 T-helper lymphocytes. Immu-
noprotection experiments have been carried out with both gp43
and P10 in combination with complete Freund’s adjuvant (CFA).
Both gp43 and P10 with CFA induce significant protective re-
sponses, as immunized mice studied 3 months after intratracheal
infection with virulent P. brasiliensis yeast cells displayed pre-
served lung architecture and few or no yeasts (39). In contrast,
nonimmunized mice had large numbers of yeasts within epitheli-
oid granulomas in all lung fields.
Immunoprotection by P10 is related to an IFN--producing
Th-1 response, since P10 immunization of IFN- or IFN-R and
interferon regulatory factor 1 (IRF-1) knockoutmicewas not pro-
tective (42). The key role of IFN- in organizing granulomas to
contain P. brasiliensis yeasts has been well characterized by other
research groups (6, 7, 9, 20, 28).
P10 has been validated as a vaccine candidate based on the
presentation of P10 by major histocompatibility complex
(MHC) molecules from different murine haplotypes (41) as
well as by human HLA-DR molecules similarly with other pro-
miscuous peptides derived from gp43 (19). Examination of
gp43 molecules from many different isolates has shown that
P10 is highly conserved in nature, with the exception of Para-
coccidioides lutzii (32, 40), which recently has been separated
from P. brasiliensis as a species. Additionally, P10 has been
shown to be immunoprotective even in formulations that do
not require CFA, such as with P10 combined with poly(lactic
acid-glycolic acid) nanoparticles (2).
Dendritic cells (DCs) are themost effective antigen-presenting
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cells and are distributed in the majority of tissues. Once active,
DCs express costimulatory molecules that may promote or regu-
late T-cell interaction. T-cell activation and proliferation can lead
to immunity or to tolerance, thus generating effector or regulatory
T cells and different patterns of cytokines (36, 37).
The regulation of T-cell response by DCs in systemic and sub-
cutaneous mycosis has been studied in Histoplasma capsulatum
(15), Coccidioides posadasii (13), Sporothrix schenckii (44), and P.
brasiliensis (1). The role of DCs in vaccination is a promising area
for study. Presently,we studied the impact of the transferenceofDCs
primedwith P10 tomice prior to or after intratracheal (i.t.) challenge
with the virulent Pb18 isolate of P. brasiliensis. We show that admin-
istration of P10-primed DCs is therapeutic in mice with established
PCM. Furthermore, we demonstrate that P10-primed DCs given
prior to challenge with P. brasiliensis significantly attenuate subse-
quentdisease.Hence, P10-primedDCsappear tobe anexcellent can-
didate for further study as a potential therapeutic for severe cases of
PCM in human patients or for development as a prophylactic for
individuals at risk for severe disease.
MATERIALS AND METHODS
Animal use and ethics statement. BALB/c, 6- to 8-week-old male mice
were bred at the University of São Paulo animal facility under specific
pathogen-free conditions. All animals were handled in accordance with
good animal practice as defined by the relevant national animal welfare
bodies, and all in vivo testing was approved by the Institutional Animal
Care and Use Committee of the University of São Paulo.
Fungal strain.VirulentP. brasiliensisPb18 yeast cells weremaintained
by weekly passages on solid Sabouraud medium at 37°C and were used
after 7 to 10 days of growth. Before experimental infection, the cultures
were grown in modifiedMcVeigh-Mortonmedium (MMcM) at 37°C for
5 to 7 days (33). The fungal cells werewashed in phosphate-buffered saline
(PBS; pH 7.2) and counted in a hemocytometer. The viability of fungal
suspensions, determined according to methods described previously by
staining with Janus green B (Merck, Darmstadt, Germany), was always
higher than 90% (21).
Dendritic cells. Bone-marrow-derivedDCswere generated according
to previously described methods (18, 23). Briefly, femurs and tibias were
flushed with 5 ml of RPMI. Bone marrow cells were differentiated into
DCs by culturing in RPMI (Vitrocell, Campinas, Brazil) supplemented
with 10% fetal calf serum (FCS; Vitrocell), 20 g/ml gentamicin (Gibco
BRL Life Technologies, NY), and recombinant cytokines GM-CSF (30
ng/ml) and IL-4 (15 ng/ml), both from Peprotech, Rocky Hill, NJ, for
seven days. On the third day, nonadherent cells were removed and further
incubated with fresh medium and growth factors. On the fifth day, the
supernatant was centrifuged, the pellet was plated again, and the medium
with growth factors was replaced. On the seventh day, the nonadherent
cells were removed and analyzed by fluorescence-activated cell sorting
(FACS; BD FACSCanto) using DC cell surface markers. Approximated
70% of the cells were CD11cMHC class II. The other cells (30%) were
granulocytes, lymphocytes, and macrophages. The macrophages dis-
played an immature phenotype, with no expression ofMHC-II, CD80, or
CD86 (data not shown).
In vitro cell proliferation induced by P10-pulsed DCs. Peptide P10
was produced as described previously (39) and diluted in PBSwith 20%of
dimethyl sulfoxide (DMSO). Footpads of mice were injected with either
10.2 M P10 (group 1) or PBS only (control, group 2). After 7 days, the
spleens were harvested and the splenocytes were dispersed manually. The
cells were collected by centrifugation (450 g), and the pellets were sus-
pended in RPMI 1640 supplemented with 20 mM NaHCO3, 10 mM
HEPES, 20 g/ml gentamicin, 2 mM L-glutamine, 50 mM -mercap-
toethanol, 5mM sodiumpyruvate, and 100mMnonessential amino acids
with 1% fetal calf serum (FCS). The splenocytes of immunized or control
mice were cultured in flat-bottom 96-well microtiter plates at a final con-
centration of 4 105 cells/well. DCs were added to the designated wells at
a 3:1 DC-to-spleen-cell ratio. The following controls were used: spleen
cells alone, with P10 only, or with P10-primedDCs. The P10-primedDCs
were generated by incubating 3  105 DCs for 2 h with 2.55 M P10.
Concanavalin A-primed DCs were also used as a control. The plates were
incubated for 72 h at 37°C and 5% CO2. Proliferation was determined
using 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bro-
mide (MTT) assays as described previously (29), and the results (based on
the optical density) are means of triplicate determinations.
Intratracheal infection of BALB/c mice. BALB/c mice were inocu-
lated intratracheally (i.t.) with virulent P. brasiliensis Pb18. Briefly, mice
were anesthetized intraperitoneally (i.p.) with 200 l of a solution con-
taining 80 mg/kg ketamine and 10 mg/kg of xylazine, both from União
Química Farmacêutica, Brazil. For inoculation, a mouse’s neck was hy-
perextended, the trachea was exposed at the level of the thyroid, and 3
105 yeast cells in PBS were injected i.t. using a 26-gauge needle. A maxi-
mum of 50 l was inoculated per mouse. Incisions were sutured with 5-0
silk.
Transference of P10-pulsed DCs into infected mice with P. brasil-
iensis. Priming of DCs was achieved by incubating 3  105 DCs with
2.55 M P10 for 2 h. The DCs were washed three times with PBS prior
to use in immunization regimens. For the therapeutic protocols, ani-
mals were infected i.t. with 3  105 yeast cells, and they subsequently
received 2 doses of 3 105 DCs primed with P10 in 50 l PBS on days
31 and 38 after infection. Groups of mice were immunized by either
intravenous (via tail vein) or subcutaneous (footpad) injection of DCs.
These mice were sacrificed 7 days after the second immunization, at
day 45 after infection. We also examined the impact of a single subcu-
taneous immunization at day 15 after infection in which mice were
sacrificed 7 days later, at day 21 after infection. For the prophylactic
protocol, mice were immunized by either intravenous (via tail vein) or
subcutaneous (footpad) routes with 3 105 DCs pulsed with P10 in 50
l PBS and then infected i.t. 24 h after immunization. The mice in the
prophylactic protocol were sacrificed 30 days after infection. For both
the treatment and prophylactic protocols, control groups included
mice that received only PBS or unprimed DCs.
Fungal burden in organs of infected mice. Mice were sacrificed at the
specified days after i.t. infection, and fungal burdens were determined by
CFU. Sections of lungs were removed, weighed, and homogenized in 1ml
of PBS. Samples (100 l) were plated on solid brain heart infusion (BHI)
medium supplemented with 4% fetal calf serum (Gibco, NY), 5% spent P.
brasiliensis (strain 192) culture medium, 10 IU/ml streptomycin-
penicillin (Cultilab, Brazil), and 500 mg/ml cycloheximide (Sigma, St.
Louis, MO) (10). Petri dishes were incubated at 37°C for at least 10 days,
and colonies were counted (1 colony 1 CFU).
Histopathological analyses. Sections of murine lungs were also fixed
in 10% buffered formalin and embedded in paraffin for sectioning. The
sections were stained by the Gomori-Grocott method and examined mi-
croscopically.
Cytokine detection. Sections of excised lungs were homogenized in 2
ml of PBS in the presence of protease inhibitors: benzamidine HCl (4
mM), EDTA disodium salt (1 mM),N-ethylmaleimide (1 mM), and pep-
statin (1.5 mM) (Sigma, St. Louis, MO). The supernatants were assayed
for IL-4, IL-10, IL-12, and IFN- using enzyme-linked immunosorbent
assay (ELISA) kits (BD OpTeia, San Diego, CA). The detection limits of
the assays were as follows: 7.8 pg/ml for IL-4, 31.3 pg/ml for IFN- and
IL-10, and 62.5 pg/ml for IL-12, as previously determined by the manu-
facturer.
Statistical analysis. Results were analyzed using GraphPad 5.0 soft-
ware (GraphPad Inc., San Diego, CA). Statistical comparisons were made
by analysis of variance (one-way ANOVA) followed by a Tukey-Kramer
posttest. All values were reported as the mean  standard error of the
mean (SEM). P values of0.05 indicated statistical significance.
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RESULTS
Cell proliferation induced by P10-primed DCs. The ability of
P10-primed DCs to induce cell proliferation of splenocytes from
animals previously immunized with P10 was demonstrated.
Splenocytes fromBALB/cmice previously immunized subcutane-
ously with P10were isolated and cocultured in the presence of P10
at 2.55Mor with P10-primed DCs. Coculture with in vitro P10-
primed DCs induced a 3-fold-higher proliferation than spleno-
cytes incubated with P10 alone (Fig. 1). The proliferation of
splenocytes incubated with P10 alone was similar to that of con-
trols without antigen.
Immunization with P10-primed DCs reduces fungal burden.
Weused several protocols to evaluate whether immunizationwith
P10-pulsed DCs could reduce fungal burdens. The experiments
were performed three different times, with a total of 15 animals for
each group tested. In the therapeutic protocol, where treatment
was initiated after 30 days of infection, the two injections of P10-
primed DCs were sufficient to significantly reduce the fungal bur-
den in the lungs of infectedmice compared to the fungal burden in
the lungs of those that did not receive any treatment or were in-
jected with unprimed DCs (Fig. 2). We also observed that both
routes of administration of the P10-primedDCs, intravenous and
subcutaneous, produced similar results. We also tested a thera-
peutic protocol in which the animals were infected i.t. and after 15
days of infection were treated with one dose of P10-primed DCs
and sacrificed 7 days after immunization. The results of this pro-
tocol were similar to those observed with the previous therapeutic
protocol after 30 days of infection (data not shown).
However, in a prophylactic protocol (Fig. 3), different results
were obtained depending on route of vaccination. Notably, a sig-
nificant reduction of the fungal burden in the lungs was achieved
when mice were immunized with the P10-primed DCs subcuta-
neously prior to infection. In contrast, mice intravenously immu-
nized with the P10-primed DCs had fungal burdens similar to
those of the infected control animals.
Cytokine pattern induced by immunization with P10-
primed dendritic cells. Cytokine levels were measured in the lung
tissueof i.t. infectedmice.As shown inFig. 4, the therapeuticprotocol
groups that received P10-pulsed DCs via either the intravenous or
subcutaneous route had significantly higher levels of the proinflam-
matory cytokines IL-12 and IFN- than the control groups. Addi-
tionally, the levels of IL-10 were significantly reduced in both P10-
pulsed-DC-treated groups, and IL-4 was not detected.
As depicted in Fig. 5, the prophylactic protocol group that
received P10-primed DCs subcutaneously had significantly in-
creased levels of IL-12 and IFN- and reduced levels of IL-10.
However, the group that received the vaccine intravenously did
not show a significant increase of IL-12 or IFN-, but IL-10 was
reduced. The IL-4 levels did not differ between groups subjected
to the prophylactic protocol.
Lung histopathology in treated, i.t. infected BALB/c mice.
The lungs of the untreated control animals showed intense infil-
trations of inflammatory cells with areas of proliferating fungal
cells. In the therapeutic protocol, mice vaccinated with P10-
FIG 1 Cell proliferation assay. Splenocytes isolated from BALB/c mice previ-
ously immunized subcutaneously with 10.2 M P10 were stimulated in vitro
for 72 h with 2.55 M P10 or with P10-primed DCs or nonprimed DCs. NS,
nonstimulated splenocytes; ConA, positive-control activation of splenocytes
with the mitogen concanavalin A. Each bar shows the mean of results from 3
experiments carried out on different days. , significant difference (P 
0.0001; determined by analysis of variance [2-wayANOVA] and the posttest of
Tukey-Kramer) relative to the free P10 stimulated system.
FIG 2 Lung CFU: therapeutic protocol. The results are from two independent
experiments. Each group from each experiment (n 5) was infected i.t. with
3  105 yeast cells. After 30 days, groups of mice received either nonprimed
dendritic cells (DCs) or P10-primed DCs via either an intravenous (IV) or
subcutaneous (SC) route. A second identical immunization was administered
7 days later. The control group (C) was not treated. Mice were sacrificed at
day 45 after infection. , significant difference (P 0.05) compared with the
control and unprimed DCs.
FIG 3 Lung CFU: prophylactic protocol. The results are from two indepen-
dent experiments. The groups of treatedmice (n 5 per experiment) received
either unprimed dendritic cells (DC) or P10-primed DCs via either intrave-
nous (IV) or subcutaneous (SC) route 24 h before the mice were infected i.t.
with 3 105 yeast cells. The control (C) group received PBS 1 day prior to
infection. Mice were sacrificed 30 days after infection. , significant difference
(P 0.001) compared with the control.
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primed DCs via intravenous or subcutaneous injection displayed
significantly less lung tissue infiltration, few intact yeast cells, and
large areaswith preserved architecture (Fig. 6). In the prophylactic
protocol, similar beneficial results were observed only in the
group of animals that received P10-primed DCs by the subcuta-
neous route. The group prophylactically treated intravenously
showed a pattern similar to that of the infected control mice
(Fig. 7).
FIG 4 Cytokine detection: therapeutic protocol. Cytokines were assayed in the lung tissue frommice 45 days after i.t. infection. Each group (n 5) was infected
i.t. with 3 105 yeast cells. After 30 days, groups of mice received either unprimed dendritic cells (DCs) through subcutaneous route or P10-primed DCs via
either an intravenous (IV) or subcutaneous (SC) route. A second identical immunizationwas administered 7 days later. The control group (C) was not treated,
and Sham represents uninfected and untreated mice. , significant difference (P 0.05) compared with C and DC groups.
FIG 5 Cytokine detection: prophylactic protocol. Cytokines were assayed in the lung tissue frommice 45 days after i.t. infection. The treatment groups (n 5)
ofmice received either unprimed dendritic cells (DCs) through the subcutaneous (SC) route or P10-primedDCs via either an intravenous (i.v.) or subcutaneous
route 24 h before themicewere infected i.t. with 3 105 yeast cells. The control (C) group receivedPBS 1day prior to infection, and Shamrepresents uninfected
and untreated mice. , significant difference (P 0.05) compared with C and DC groups.
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DISCUSSION
Current antimicrobial regimens for paracoccidioidomycosis re-
quire months to years of administration, carry risks for serious
side effects, and result in frequent relapses (reviewed in reference
35). Peptide P10 induces strong, protective immunological re-
sponses, which makes it a lead candidate for a therapeutic vaccine
against paracoccidioidomycosis. With or without adjunctive che-
motherapy, P10 coadministered with adjuvant is highly effective
at reducing the burden of P. brasiliensis from infected mice
(24, 39).
DCs are potent stimulators of the immune response. Most im-
portantly, they are capable of activating naive T cells by presenting
peptide antigens and expressing high levels of costimulatory mol-
ecules (reviewed in reference 4). In the vaccine formulation used
in this work, DCs were incubated with the peptide for 2 h, which
provided sufficient time for the immature DCs to capture peptide
antigens directly from the extracellular medium and rapidly dis-
play them for subsequent presentation to T lymphocytes (34).
DCs can stimulate T cells at low concentrations of P10, and a
single dendritic cell is able to activate 100 to 3,000T cells (reviewed
in reference 5). An additional benefit of DC vaccination is that
adjuvants are not necessary.
The in vitro sensitized cell proliferation experiment showed
that P10 at a concentration of 2.55was not sufficient to induce
splenocyte proliferation. However, coculture of splenocytes with
DCs preincubated with 2.55  P10 resulted in significant
splenoncyte proliferation. These results highlight the efficiency of
DCs in antigen presentation and initiation of cellular response,
with activation of sensitized or naive T cells (38).
In the present work, we examined the administration of P10-
primedDCs via intravenous and subcutaneous routes.We studied
the subcutaneous route, as previous reports show that injection of
DCs into footpads resulted in the migration of significant num-
bers of these cells into draining lymphnodeswithin 24 h (3, 25). In
our treatment protocols, we found that injection of primed DCs
via either the intravenous or subcutaneous route in established
PCM produced similar protective results, both in reducing fungal
burden and stimulating a Th1-biased cytokine response. How-
ever, the route of vaccination was of critical importance when
P10-primed DCs were administered prior to challenge with P.
brasiliensis. Although subcutaneous vaccination led to lower pul-
monary fungal burdens and Th1-biased cytokine responses, dis-
ease in mice that received intravenous vaccination with P10-
primed DCs was similar to that in infected control animals.
Hence, subcutaneously administered P10-primed DCs that mi-
grated to draining lymph nodes were more effective in activating
naïve T cells to elicit a Th1-biased response compared to DCs
injected intravenously. The systemic injection of DCs results in
their preferential distribution on the lungs, liver, and spleen (14,
17, 22, 30). The preferential migration of the intravenously in-
jected DCs to the lungs prior to challenge with P. brasiliensismay
result in tolerance to the targeted antigen and increasing suscep-
tibility of the animal to subsequent infection, similar to what oc-
curs with allergic sensitization (16). The effect is different in the
presence of established P. brasiliensis disease. In this situation, the
intravenously administered P10-primed DCs that rapidly mi-
grated to the lung found an inflammatory environment ripe for
regulation.
The cytokines assayed in this study were those that are related
to the two major types of immune response in paracoccidioido-
mycosis. IFN- and IL-12 are representative of a Th1 response,
which is protective against the fungal agent (2, 6, 7). In contrast,
IL-4 and IL-10 are representative of a Th2 response, which aggra-
vates the disease (2, 6). However, depending on the degree of
inflammation caused by the Th1 response, the anti-inflammatory
Th2 cytokines are essential to reach a balance with the Th1 cyto-
kines in order to generate an appropriate protective immune re-
sponse (42). The cytokine milieu achieved in infected mice after
the intravenous or subcutaneous administration of P10-primed
DCs demonstrated increased levels of Th1 cytokines with a con-
comitant decrease in Th2 cytokines. In contrast, only the subcu-
taneous administration of P10-primedDCs resulted in an increase
in Th1 cytokines, and there was a mixed Th2 response, with
FIG 6 Representative lung sections: therapeutic protocol. Histopathological
sections of murine lungs 45 days after i.t. infection. (A) Representative section
of lung from an infected and untreatedmouse. For treatment, mice received at
day 30 and 38 either unprimed DCs subcutaneously (B) or P10-primed DCs
intravenously (C) or subcutaneously (D). Photographs of sections were taken
at 400magnification.
FIG 7 Representative lung sections: prophylactic protocol. Representative
histopathological sections of murine lungs 30 days after i.t. infection. Twenty-
four hours prior to infection, mice received PBS (A), unprimed DCs subcuta-
neously (B), P10-primed DCs intravenously (C), or P10-primed DCs subcu-
taneously (D). Photographs of sections were taken at 400magnification.
P10-Primed Dendritic Cell Paracoccidioides Vaccine
January 2012 Volume 19 Number 1 cvi.asm.org 27
only IL-10 decreasing. Histopathology of themice that received
P10-primed DCs intravenously or subcutaneously after infec-
tion was established or subcutaneously prior to challenge with
P. brasiliensis revealed that the lungs of these mice had signifi-
cantly lower numbers of epithelioid granulomas with reduced
numbers of viable yeast cells, as confirmed by CFU studies, and
large areas of preserved lung tissue. Although the intravenous
administration of P10-primed DCs also reduced the concen-
trations of IL-4, it did not simulate increases in Th1 cytokines,
and the fungal burdens and inflammatory changes in the lungs
of these mice were similar to infected controls. These results
reinforce the import of Th1 responses in protecting against
progressive or severe paracoccidioidomycosis. In the therapeu-
tic groups, the ratios of IFN-/IL-10 in the mice immunized
with P10-primed DCs and challenged with P. brasiliensis were
3- to 5-fold higher than those immunized with unprimed DCs,
clearly pointing to the induction of a Th1 response by the P10-
primed DCs. This result confirms that a type-1 immune cellu-
lar response is the protective pattern in PCM.
In summary, the results show that P10-primed DCs can be
protective when administered prior to challenge with P. brasilien-
sis and that the P10-primed DCs are therapeutic in the setting of
established PCM. The effective vaccination routes induce strong
Th1-biased responses. Since DCsmay bemore efficient than non-
specific commercial adjuvants, we propose that P10-primed DCs
represent an important therapeutic to pursue for use in the pre-
vention and treatment of paracoccidioidomycosis.
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